Clear evidence this week that Eisai and Biogen’s drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer’s researchers toward a tantalizing goal – preventing dementia even before symptoms start.
Tag Archive for: Eisai
Today’s promising results from Eisai and Biogen’s Alzheimer’s drug trial have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.
An experimental Alzheimer’s drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
The biopharma industry’s response to the global pandemic has propelled some COVID-19 vaccines into the leading ranks of the world’s best-selling products, with Pfizer/BioNTech’s Comirnaty surpassing AbbVie’s Humira for the No. 1 spot.
The agency will expedite its review of Eisai Co Ltd’s (4523.T) and Biogen Inc’s (BIIB.O) experimental Alzheimer’s drug lecanemab, with a decision due by Jan 6, 2023, the companies said on Tuesday.
Biogen indicated it has terminated an observational study of its approved Alzheimer’s drug Aduhelm (aducanumab-avwa) following its post on ClinicalTrials.gov.